Key Takeaways
  • MOTS-c is not approved by the FDA for any indication, in any form, by any route. Nothing in the 2026 policy changes that.
  • On October 28, 2026, HHS issued an interim enforcement discretion policy, published in the Federal Register on October 30, 2026 (document 2026-22192, docket HHS-OASH-2026-0496).
  • HHS states it does not intend to act against a State-licensed pharmacy, a Federal facility or a licensed physician compounding MOTS-c acetate for subcutaneous or intramuscular injection, but only if all ten conditions are satisfied.
  • Those conditions include a patient-specific prescription, a single active ingredient (so no blends), an FDA-registered and CGMP-compliant original manufacturer whose physical location appears on the certificate of analysis, MedWatch reporting, and the label statement "This is a compounded drug product. Not for resale."
  • The only delivery device allowed to be co-packaged with or to contain the product is an FDA 510(k)-cleared syringe, which on a plain reading leaves pre-filled injector pens outside the policy.
  • This is neither an approval nor an addition to the 503A bulks list. FDA's CDER had recommended against listing MOTS-c, and HHS says it may revisit the policy if a safety signal or a product quality issue arises.
  • The policy does not cover research-use-only products, does not extend to 503B outsourcing facilities, and has no effect outside the United States.

Is MOTS-c an FDA-approved medicine?

No. MOTS-c has never been approved by the U.S. Food and Drug Administration for any medical indication, in any pharmaceutical form, by any route of administration. There is no New Drug Application, no Biologics License Application and no abbreviated approval covering it. There is also no United States Pharmacopeia monograph for the substance. If you are looking for a short answer before reading further, that is the one that matters most: a product containing MOTS-c is not an approved medicine in the United States.

This single fact is frequently blurred in online discussion, and the confusion became worse in late 2026. On October 28, 2026, the Department of Health and Human Services (HHS) issued an interim enforcement discretion policy covering six peptide bulk drug substances, MOTS-c among them. An enforcement discretion policy is a statement about how an agency intends to use its own enforcement resources. It is not a marketing authorisation, and it does not confer approved status on the underlying substance.

The practical consequence is that MOTS-c now sits in an unusual middle category. It remains an unapproved drug substance, yet a defined and narrow route exists through which a licensed prescriber and a compounding pharmacy may prepare it for one identified patient without HHS intending to take action, provided a long list of requirements is met. That route is the sole subject of this page.

This article deliberately does not revisit what MOTS-c is thought to do in the body, how it is believed to signal, or what the laboratory literature reports about its effects. Those questions belong to the general MOTS-c guide. What follows is about the prescription and pharmacy preparation pathway in the United States, and about the limits of that pathway.

This page is educational only. It is not medical advice, not legal advice, and not a recommendation to obtain or use any peptide. Decisions about any unapproved substance belong with a qualified, licensed healthcare professional who knows your medical history.

What changed in the United States in October 2026?

HHS announced the Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances on October 28, 2026. A notice of availability was published in the Federal Register on October 30, 2026, carrying document number 2026-22192, with a public docket at HHS-OASH-2026-0496. The notice came from the Office of the Assistant Secretary for Health, not from the FDA, which is itself notable: the policy is the Secretary's, and it sits above the agency that normally handles compounding questions.

The policy identifies six peptide bulk drug substances in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Appendix B then sets out, peptide by peptide, the chemical identity that HHS means, the routes of administration it considers appropriate, the reasoning behind each inclusion, and a testing standard for the certificates of analysis that must accompany the raw material.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional pharmacy compounding for an individual patient. A bulk drug substance may generally be used in 503A compounding if it has a USP monograph, is a component of an approved drug, or appears on a list that the FDA develops through rulemaking, known as the 503A bulks list. MOTS-c satisfies none of those. The 2026 policy is explicitly framed as a stopgap that operates while that rulemaking is still under way.

For MOTS-c specifically, Appendix B identifies the substance as MOTS-c acetate and states that enforcement discretion is appropriate for subcutaneous or intramuscular injectable preparations compounded from active ingredient accompanied by a certificate of analysis meeting the policy's conditions. No other route is covered for this peptide. Oral, nasal, topical and intravenous preparations of MOTS-c fall outside the policy.

The notice described the document as a draft and invited public comment for two weeks following publication, placing the deadline in mid-November 2026. HHS also stated that the policy does not establish any rights for any person and is not binding on HHS or on the public. Readers who want the broader picture of how peptide legality is structured in different jurisdictions can see our overview of peptide legal status.

Which pharmacies and prescribers does the policy cover?

The policy names its covered parties narrowly. HHS states that it does not intend to take action against a State-licensed pharmacy, a Federal facility, or a licensed physician that compounds a drug product using a peptide bulk drug substance listed in Appendix A, subject to the conditions. That three-item list is the whole scope of the protected activity.

Two details in that phrasing are easy to miss. First, the protection attaches to the compounder, not to the patient, not to a distributor, and not to a supplier of the raw material. Second, a licensed physician is included alongside pharmacies, which reflects the structure of section 503A itself, but the physician has to be doing the compounding to come within the policy's terms.

Equally important is the temporal framing. The policy states that the enforcement posture holds until a peptide bulk drug substance is addressed in a final rule as being included or not included on the 503A bulks list. In other words, the clock is running on an FDA rulemaking process, and the outcome of that process could remove MOTS-c from this pathway entirely.

HHS added a separate and unambiguous reservation: it may revisit the application of the interim policy, in whole or in part, if a safety signal or a product quality issue arises with a compounded product within the policy's scope. This is not a grant of stability. It is a conditional and revocable statement of intent that the agency has reserved the right to withdraw.

Because the policy is non-binding by its own terms, it also does not create a defence that a pharmacy or prescriber can rely on as a matter of right. State boards of pharmacy and state medical boards retain their own authority, and state law can be more restrictive than the federal position. Any practitioner reading this should be taking advice from counsel rather than from an article.

What conditions must all be met?

The policy sets out ten conditions, and the enforcement posture applies only where every one of them is satisfied. Failing a single condition takes the preparation outside the policy. The conditions, as set out in the HHS document, are these:

  • Interim access list. The peptide bulk drug substance appears in Appendix A to the policy.
  • Identity of the substance. The substance has the identity and the limitations on route of administration described in Appendix B. For MOTS-c, that means MOTS-c acetate, by subcutaneous or intramuscular injection only.
  • Characterisation. The substance comes from a facility registered under section 510 and is characterised and identified in a valid certificate of analysis whose test results are consistent with the guidance-based criteria described by the FDA in Appendix B.
  • Manufacturer registration and compliance. The original manufacturer of the bulk drug substance is registered with the FDA under section 510, is in compliance with current good manufacturing practice (CGMP) and other statutory requirements, and the physical location of the facility is listed on the certificate of analysis provided to the 503A compounder.
  • Reporting. The compounder reports products compounded, serious adverse events associated with human use, and product quality issues, to the FDA through the MedWatch programme and to the relevant states.
  • Product labeling. The labeling includes the statement "This is a compounded drug product. Not for resale."
  • Single active ingredient. The compounded product contains only a single active pharmaceutical ingredient, and that ingredient must itself be listed in Appendix A. Combination products and multi-peptide blends are therefore outside the policy.
  • Route of administration. Where a peptide is compounded in an oral form, the compounder is expected to keep documentation that the specific formulation achieves adequate oral bioavailability in humans. For MOTS-c this is moot, since Appendix B limits it to injection.
  • Drug delivery device. The only delivery device co-packaged with or containing the compounded product is an FDA 510(k)-cleared syringe.
  • All other applicable requirements. The product is compounded in compliance with everything else the statute requires, including that it not be compounded under insanitary conditions, and including section 503A's patient-specific prescription requirement.

That last condition is where the prescription itself lives. The policy does not create a standalone "valid prescription" clause; instead it folds the requirement in by reference to section 503A, which permits traditional compounding only for an identified individual patient based on a valid prescription. Compounding a batch in anticipation of future demand, or supplying a product to someone who is not an identified patient of the prescriber, does not fit the statute and so does not fit the policy.

Read together, these conditions describe a conventional pharmacy preparation for one named person, made from well-documented raw material, labelled as compounded, not resold, and reported on if something goes wrong. They do not describe a consumer product.

What must the certificate of analysis show?

Appendix B is where the policy becomes technical. Alongside the chemical identity of each peptide, it contains a testing standard for peptides used in compounding, laid out as a table of quality attributes, acceptable analytical methods, acceptance criteria and the relevant regulatory references. This standard appears to apply across the listed peptides rather than being written specifically for MOTS-c.

The attributes covered include appearance by visual inspection; identification and primary sequence, to be established using orthogonal analytical methods such as quantitative amino acid analysis, peptide mapping by chemical or enzymatic cleavage, and high-performance liquid chromatography co-elution against a reference standard; purity and related substances by HPLC and reverse-phase HPLC; counter-ion content, which matters for an acetate salt; water content by Karl Fischer titration; residual solvents by gas chromatography; bacterial endotoxins by LAL testing under USP chapter 85; and microbial testing. For injectable preparations, the appendix adds that the testing should include the tests specific to that route.

The certificate is also expected to carry administrative content: manufacturer information, batch number, dates of synthesis and release, an expiration date, a statement of the pharmaceutical form, storage conditions, and a statement that the material was manufactured and tested in compliance with CGMP. It should identify the analytical method used, including the method name and number, and testing may be performed using established compendial procedures or verified compendial methods.

One honest caveat is worth stating plainly, because it is often misreported. The acceptance criteria in the appendix are expressed largely by reference to USP and ICH standards rather than as specific numbers printed in the document, and no MOTS-c-specific numeric purity or impurity threshold was identifiable in the policy text. Any article that quotes a precise percentage as an HHS requirement should be treated with caution. Note too that endotoxin and microbial testing are not the same thing as a sterility specification, and the appendix lists the former.

Why does this granularity matter to a reader rather than to a chemist? Because the entire logic of the policy rests on it. HHS is not saying that MOTS-c has been shown to be safe and effective. It is saying that if the raw material is traceable, documented and tested to a recognised standard, the risk profile of a patient-specific compounded preparation is different from that of an undocumented product of unknown provenance. The documentation is the policy. Our discussion of what is and is not known about peptide safety gives the wider context for why material quality carries so much weight here.

Why does the text permit only a 510(k)-cleared syringe?

Condition nine is short, and it is probably the most consequential sentence in the policy for anyone thinking about how a product would actually be supplied. It states that the only drug delivery device co-packaged with or containing the compounded drug is an FDA 510(k)-cleared syringe.

The construction is exclusive rather than permissive. The text does not say that a syringe is among the devices permitted; it says a 510(k)-cleared syringe is the only one. On a plain reading, that places other delivery systems outside the policy. A pre-filled injector pen, an autoinjector, a cartridge-based device or a nasal spray device co-packaged with the product would not satisfy the condition, and a preparation supplied that way would therefore fall outside the enforcement posture even if every other condition were met.

There is a defensible regulatory reason for this. A 510(k) clearance means the device has gone through FDA premarket notification and been found substantially equivalent to a legally marketed predicate. A pen or autoinjector loaded with an unapproved drug substance raises a combination product question that the policy simply does not attempt to resolve. Restricting the permitted device to a cleared syringe keeps the policy inside well-mapped territory.

One genuine ambiguity should be flagged rather than papered over. The restriction is worded around devices co-packaged with or containing the compounded drug. It is less obvious how it applies to a device a patient already owns separately, and no language resolving that edge case was identifiable in the policy. That is a question for a pharmacist and for counsel, not something an article should answer with confidence.

The broader point for a reader is that the permitted presentation under this policy is narrow and conventional: a single-ingredient injectable preparation, for one named patient, supplied with a cleared syringe, carrying a compounded-product label. Presentations that look like consumer convenience products are not what the policy describes.

What does this policy not do?

Several things need saying directly, because the October 2026 announcement was widely summarised as though MOTS-c had been authorised. It was not.

It is not an approval. The policy does not approve any peptide and does not alter the regulatory status of the substances. Compounded preparations are not FDA-approved products: nobody has reviewed a MOTS-c preparation for safety, effectiveness, manufacturing consistency or labelling accuracy in the way that an approval requires.

It is not a listing. The policy does not add MOTS-c, or any of the six peptides, to the 503A bulks list. It operates precisely because that list is still being developed through rulemaking, and the HHS document notes that future FDA rulemaking may propose adding some or all of these peptides based on the available evidence. Equally, it may not.

It is temporary, and it is revocable. The stated posture holds only until a final rule addresses each substance, and HHS expressly reserved the ability to revisit the policy in whole or in part if a safety signal or product quality issue emerges. The document also states that it does not establish rights for any person and is not binding on HHS or the public.

The scientific record was not the reason for inclusion. This is the part most often left out. At the Pharmacy Compounding Advisory Committee meeting of July 23 and 24, 2026, the FDA's Center for Drug Evaluation and Research (CDER) reviewed MOTS-c, in both free base and acetate forms, for the nominated uses of obesity and osteoporosis, and recommended against including it on the 503A bulks list, citing a record that lacked human safety and effectiveness data and lacked adequate characterisation and impurity information. The advisory committee voted in favour of inclusion. HHS then built its own justification in Appendix B around improved characterisation records for the acetate form and available safety evidence, which for MOTS-c included a randomised placebo-controlled trial of a MOTS-c analogue that reported no serious adverse events. An analogue is not the same molecule. A reader is entitled to notice that the agency's own scientific reviewers reached the opposite conclusion about this peptide.

In short: a pathway existing is not the same as a substance being validated. The evidence base for MOTS-c in humans remains thin, and no amount of regulatory plumbing changes that.

How are research-use-only products and 503B facilities treated?

The policy's treatment of research-use-only material is one of its clearest signals, and it runs in the opposite direction from how the announcement is sometimes presented. The Secretary of HHS determined that this limited enforcement-discretion policy will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients.

That framing is worth sitting with. Discouraging research-use-only supply is stated as a purpose of the policy, not an incidental consequence. The pathway exists to pull activity toward licensed pharmacies working with documented, FDA-registered, CGMP-compliant raw material, and away from vials labelled for laboratory use that reach individuals through other channels. Material sold as research-use-only, as a chemical, or as a supplement is not covered by the policy and gains nothing from it.

503B outsourcing facilities are also outside the policy. The document addresses section 503A compounding, and its covered-party list consists of State-licensed pharmacies, Federal facilities and licensed physicians. Outsourcing facilities, which operate under section 503B and compound at larger scale without patient-specific prescriptions, are not among those parties and the policy does not independently extend enforcement discretion to them.

The combined effect is a deliberately narrow channel. A preparation made for one identified patient, by a State-licensed pharmacy, from registered and documented raw material, as a single active ingredient, labelled as compounded and not for resale, supplied with a cleared syringe. Anything wider than that, in volume, in presentation, in ingredient count or in supply chain, is not what HHS described.

It also follows that nothing in this policy supports commercial sale to the public. The required label statement, "This is a compounded drug product. Not for resale.", exists precisely to foreclose that reading.

Does anything change outside the United States?

No. The HHS enforcement discretion policy is an instrument of United States federal administrative practice. It describes how one U.S. department intends to exercise its enforcement authority under the Federal Food, Drug, and Cosmetic Act. It has no legal effect in any other country and confers no status on MOTS-c anywhere else.

MOTS-c has no marketing authorisation from the European Medicines Agency, and the compounding frameworks in the European Union, the United Kingdom, Canada, Australia and elsewhere are structured differently from sections 503A and 503B. Those systems have their own rules on magistral and officinal preparation, their own requirements for pharmaceutical-grade starting materials, and their own positions on unlicensed medicines. None of them is altered by a Federal Register notice.

Importation is a separate matter again, and a stricter one in many places. The fact that a U.S. pharmacy may prepare something for a U.S. patient under a U.S. policy says nothing about whether a substance may lawfully be imported, possessed or administered elsewhere. Readers outside the United States should treat this policy as background information about one jurisdiction rather than as guidance applicable to their own.

Anti-doping rules are also untouched. Regulatory enforcement posture and sporting eligibility are entirely separate systems, and a compounded preparation lawfully dispensed under a prescription can still breach the rules of a sporting body. Anyone subject to testing needs to check the current prohibited list and seek advice specific to their situation.

Our guide to peptide legal status across jurisdictions covers the structural differences in more detail, and the general MOTS-c guide addresses the scientific questions that sit outside the scope of this page.

What should you ask a clinician and a pharmacy?

If a prescriber or a pharmacy raises the subject of a compounded MOTS-c preparation, the October 2026 policy gives you a precise checklist against which the offer can be measured. These are questions about documentation and regulatory fit, not requests for a recommendation, and a competent professional should be able to answer every one of them without hesitation.

Questions for the clinician:

  • MOTS-c is not FDA approved for any indication. What is your clinical reasoning for raising it in my particular case, and what are the alternatives that are approved?
  • What does the human evidence base actually consist of, and are you aware that FDA's own reviewers recommended against listing this substance in July 2026?
  • How will you monitor me, what would make you stop, and how will serious adverse events or product quality problems be reported through MedWatch?
  • Are you compounding this yourself, or prescribing to a State-licensed pharmacy, and is the prescription written for me specifically as an identified patient?
  • What is your position if HHS withdraws or revises this interim policy while I am under your care?

Questions for the pharmacy:

  • Will you provide the certificate of analysis for the active ingredient lot, and does it state the physical location of the original manufacturing facility?
  • Is that original manufacturer registered with the FDA under section 510 and CGMP compliant?
  • Does the certificate cover identity and primary sequence by orthogonal methods, purity and related substances, counter-ion content, water content, residual solvents, bacterial endotoxins and microbial testing?
  • Is the substance supplied as MOTS-c acetate, and is the preparation for subcutaneous or intramuscular injection, as Appendix B requires?
  • Does the preparation contain a single active ingredient only, with no other peptide included?
  • Does the label carry the statement "This is a compounded drug product. Not for resale."?
  • Is the only device supplied with it an FDA 510(k)-cleared syringe?

Any gap in those answers is meaningful. A preparation that misses one condition is not a slightly less compliant version of the same thing; it sits outside the policy altogether. In particular, an offer involving a multi-peptide blend, a pre-filled injector pen, material described as research-use-only, or a supply arrangement without a patient-specific prescription does not match what HHS described, whatever the policy is said to permit.

Medical disclaimer. This article is for educational purposes only and is a summary of a regulatory position, not clinical guidance. It contains no recommendation to use MOTS-c, no administration instructions and no amounts, and nothing here should be read as encouragement to obtain any peptide. MOTS-c is not approved by the FDA or the EMA. Much of the available research is preclinical, and preclinical findings do not establish safety or effectiveness in people. Always consult a qualified, licensed healthcare professional before considering any unapproved substance, and be aware that legal status varies by jurisdiction.

Recommended products

Research peptides selected for quality and purity:

Test your knowledge

Quick quiz · 6 questions

Frequently Asked Questions

Is MOTS-c approved by the FDA in 2026?
No. MOTS-c is not approved by the FDA for any indication, in any pharmaceutical form, by any route of administration, and there is no USP monograph for it. The HHS enforcement discretion policy of October 28, 2026 does not change this. An enforcement discretion policy is a statement about how a department intends to use its enforcement resources; it is not a marketing authorisation, and compounded preparations are not FDA-approved products.
Does the HHS policy make MOTS-c legal to sell to consumers?
No. The policy covers only a State-licensed pharmacy, a Federal facility or a licensed physician compounding a preparation for an identified individual patient under section 503A, which requires a patient-specific prescription. One of the ten conditions requires the labeling to state "This is a compounded drug product. Not for resale." Material sold as research-use-only, as a chemical or as a supplement is not covered, and HHS stated that one purpose of the policy is to discourage continued widespread use of research-use-only peptides from foreign manufacturers.
Can a pharmacy combine MOTS-c with another peptide under this policy?
No. The policy requires that the compounded product contain only a single active pharmaceutical ingredient, and that the ingredient itself be listed in Appendix A. A blend containing MOTS-c plus any other peptide falls outside the enforcement discretion, even if the second peptide is also one of the six listed substances. Because all ten conditions have to be satisfied together, failing this one takes the whole preparation outside the policy.
Does the policy allow a pre-filled injector pen?
On a plain reading of the text, no. The condition states that the only drug delivery device co-packaged with or containing the compounded drug is an FDA 510(k)-cleared syringe. The wording is exclusive rather than permissive, which leaves pens, autoinjectors, cartridge devices and nasal spray devices outside the policy. There is a genuine ambiguity about a device a patient already owns separately, and the policy text does not resolve it, so that question belongs with a pharmacist and with counsel.
How long will the HHS enforcement discretion last?
It is explicitly temporary. The policy states that the posture holds until each peptide bulk drug substance is addressed in a final rule as being included or not included on the 503A bulks list, which is a process the FDA is still working through. HHS also reserved the right to revisit the policy in whole or in part if a safety signal or a product quality issue arises, and stated that the document is not binding on HHS or the public and establishes no rights for any person.
Does this policy apply in Canada, the United Kingdom or the European Union?
No. The policy is an instrument of United States federal administrative practice under the Federal Food, Drug, and Cosmetic Act and has no legal effect elsewhere. MOTS-c holds no EMA marketing authorisation, and other countries run their own frameworks for pharmacy preparation and unlicensed medicines, with their own requirements for starting materials. Importation rules are a separate and often stricter matter, and anti-doping rules are unaffected by any regulatory enforcement posture.

Sources

  1. U.S. Department of Health and Human Services (2026). HHS 503A Peptide Enforcement Discretion Policy, Appendix B: Peptide Identities and Justifications (includes the MOTS-c acetate entry and the testing standard for peptides used in compounding). HHS.gov. (hhs.gov)
  2. U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health (2026). Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability; document 2026-22192; docket HHS-OASH-2026-0496). Federal Register. (federalregister.gov)
  3. U.S. Department of Health and Human Services (2026). HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (main policy document, including the ten conditions). HHS.gov. (hhs.gov)
  4. U.S. Food and Drug Administration (2026). July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (bulk drug substances nominated for inclusion on the section 503A bulks list). FDA.gov. (fda.gov)
  5. U.S. Food and Drug Administration (2026). Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. FDA.gov. (fda.gov)
  6. Lee C, Zeng J, Drew BG, et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism (PMID 25738459). (PubMed)
  7. Gao Y, Wei X, Wei P, et al. (2023). MOTS-c functionally prevents metabolic disorders. Metabolites (PMID 36677050). (PubMed)
  8. Reynolds JC, Lai RW, Woodhead JST, et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. (nature.com)
  9. Krier JD, Zhu X, Lerman A, et al. (2026). Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation and remain unchanged after weight loss. Journal of Clinical and Translational Endocrinology (PMID 41551324). (PubMed)
  10. Cataldo LR, Fernández-Verdejo R, Santos JL, Galgani JE (2018). Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. Journal of Investigative Medicine (PMID 29593067). (PubMed)
  11. EpiVax, U.S. FDA and CUBRC investigators (2025). Immunogenicity risk assessment of peptide-related impurities identified in generic teriparatide products. Frontiers in Immunology (PMID 41445733). (PubMed)

This content is for informational and educational purposes only. It does not constitute medical advice. Consult a healthcare professional before making any decisions. Read our full medical disclaimer